CN102089035A - 抗血小板治疗中血小板抑制的维持 - Google Patents
抗血小板治疗中血小板抑制的维持 Download PDFInfo
- Publication number
- CN102089035A CN102089035A CN2009801266781A CN200980126678A CN102089035A CN 102089035 A CN102089035 A CN 102089035A CN 2009801266781 A CN2009801266781 A CN 2009801266781A CN 200980126678 A CN200980126678 A CN 200980126678A CN 102089035 A CN102089035 A CN 102089035A
- Authority
- CN
- China
- Prior art keywords
- described method
- reversible
- inhibitor
- fugitive
- main body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000005764 inhibitory process Effects 0.000 title claims description 20
- 238000013176 antiplatelet therapy Methods 0.000 title description 15
- 238000012423 maintenance Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 76
- 230000002441 reversible effect Effects 0.000 claims abstract description 71
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 238000013146 percutaneous coronary intervention Methods 0.000 claims abstract description 9
- 239000002184 metal Substances 0.000 claims abstract description 6
- 210000004351 coronary vessel Anatomy 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 51
- 229960001080 cangrelor Drugs 0.000 claims description 47
- PAEBIVWUMLRPSK-IDTAVKCVSA-N cangrelor Chemical group C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O PAEBIVWUMLRPSK-IDTAVKCVSA-N 0.000 claims description 47
- 229940125670 thienopyridine Drugs 0.000 claims description 46
- 239000002175 thienopyridine Substances 0.000 claims description 46
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 38
- 229960003009 clopidogrel Drugs 0.000 claims description 38
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 38
- 230000009545 invasion Effects 0.000 claims description 38
- 238000001802 infusion Methods 0.000 claims description 33
- 239000002172 P2Y12 inhibitor Substances 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 18
- 238000001990 intravenous administration Methods 0.000 claims description 13
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 12
- 230000002427 irreversible effect Effects 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 238000002651 drug therapy Methods 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 abstract description 40
- 238000001356 surgical procedure Methods 0.000 abstract description 23
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract description 13
- 208000007536 Thrombosis Diseases 0.000 abstract description 12
- 230000000302 ischemic effect Effects 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 6
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 abstract description 5
- 206010000891 acute myocardial infarction Diseases 0.000 abstract description 5
- 208000007814 Unstable Angina Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000002792 vascular Effects 0.000 abstract description 2
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000007718 Stable Angina Diseases 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 25
- 229960001138 acetylsalicylic acid Drugs 0.000 description 25
- 208000032843 Hemorrhage Diseases 0.000 description 20
- 229940079593 drug Drugs 0.000 description 10
- 239000003146 anticoagulant agent Substances 0.000 description 9
- 208000034158 bleeding Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 238000011977 dual antiplatelet therapy Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000702 anti-platelet effect Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- LGSDFTPAICUONK-UHFFFAOYSA-N elinogrel Chemical compound O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(Cl)S1 LGSDFTPAICUONK-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229960005001 ticlopidine Drugs 0.000 description 3
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010071229 Procedural haemorrhage Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000013171 endarterectomy Methods 0.000 description 2
- 238000002674 endoscopic surgery Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960004197 prasugrel Drugs 0.000 description 2
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 208000037486 Postoperative Hemorrhage Diseases 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12741408P | 2008-05-13 | 2008-05-13 | |
| US61/127,414 | 2008-05-13 | ||
| PCT/US2009/043820 WO2009140407A1 (en) | 2008-05-13 | 2009-05-13 | Maintenance of platelet inhibition during antiplatelet therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102089035A true CN102089035A (zh) | 2011-06-08 |
Family
ID=41319000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801266781A Pending CN102089035A (zh) | 2008-05-13 | 2009-05-13 | 抗血小板治疗中血小板抑制的维持 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8871736B2 (https=) |
| EP (1) | EP2276541B1 (https=) |
| JP (2) | JP5792059B2 (https=) |
| CN (1) | CN102089035A (https=) |
| AU (1) | AU2009246396B2 (https=) |
| BR (1) | BRPI0912693B8 (https=) |
| CA (1) | CA2724470C (https=) |
| CY (1) | CY1118653T1 (https=) |
| DK (1) | DK2276541T3 (https=) |
| ES (1) | ES2601524T3 (https=) |
| HR (1) | HRP20161443T1 (https=) |
| HU (1) | HUE031704T2 (https=) |
| LT (1) | LT2276541T (https=) |
| PL (1) | PL2276541T3 (https=) |
| PT (1) | PT2276541T (https=) |
| SI (1) | SI2276541T1 (https=) |
| WO (2) | WO2009140092A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110740736A (zh) * | 2017-06-23 | 2020-01-31 | 奇斯药制品公司 | 预防体-肺动脉分流术血栓形成的方法 |
| CN115120606A (zh) * | 2013-03-09 | 2022-09-30 | 奇斯药制品公司 | 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 |
Families Citing this family (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US20130303477A1 (en) | 2008-05-13 | 2013-11-14 | The Medicines Company | Maintenance of Platelet Inhibition During Antiplatelet Therapy |
| US20120141468A1 (en) * | 2008-05-13 | 2012-06-07 | Lisa Ruderman Chen | Maintenance of platelet inhibition during antiplatelet therapy |
| WO2009140092A1 (en) | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US8759316B2 (en) | 2008-05-13 | 2014-06-24 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US8680052B1 (en) * | 2013-03-09 | 2014-03-25 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| PT2498731T (pt) * | 2009-11-11 | 2020-02-21 | Chiesi Farm Spa | Métodos de tratamento ou prevenção de uma trombose de endoprótese |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| AU2012214396B2 (en) * | 2011-02-09 | 2017-04-27 | Chiesi Farmaceutici S.P.A. | Methods for treating pulmonary hypertension |
| US11871901B2 (en) | 2012-05-20 | 2024-01-16 | Cilag Gmbh International | Method for situational awareness for surgical network or surgical network connected device capable of adjusting function based on a sensed situation or usage |
| WO2014209389A1 (en) * | 2013-06-26 | 2014-12-31 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US11504192B2 (en) | 2014-10-30 | 2022-11-22 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
| EP3244900A4 (en) | 2015-01-14 | 2018-05-30 | Chiesi Farmaceutici S.p.A. | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
| US11564756B2 (en) | 2017-10-30 | 2023-01-31 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
| US11801098B2 (en) | 2017-10-30 | 2023-10-31 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
| US11911045B2 (en) | 2017-10-30 | 2024-02-27 | Cllag GmbH International | Method for operating a powered articulating multi-clip applier |
| US11229436B2 (en) | 2017-10-30 | 2022-01-25 | Cilag Gmbh International | Surgical system comprising a surgical tool and a surgical hub |
| US11141160B2 (en) | 2017-10-30 | 2021-10-12 | Cilag Gmbh International | Clip applier comprising a motor controller |
| US11317919B2 (en) | 2017-10-30 | 2022-05-03 | Cilag Gmbh International | Clip applier comprising a clip crimping system |
| US11051836B2 (en) | 2017-10-30 | 2021-07-06 | Cilag Gmbh International | Surgical clip applier comprising an empty clip cartridge lockout |
| US11510741B2 (en) | 2017-10-30 | 2022-11-29 | Cilag Gmbh International | Method for producing a surgical instrument comprising a smart electrical system |
| US11291510B2 (en) | 2017-10-30 | 2022-04-05 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
| US11311342B2 (en) | 2017-10-30 | 2022-04-26 | Cilag Gmbh International | Method for communicating with surgical instrument systems |
| US11304720B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Activation of energy devices |
| US20190201090A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Capacitive coupled return path pad with separable array elements |
| US11571234B2 (en) | 2017-12-28 | 2023-02-07 | Cilag Gmbh International | Temperature control of ultrasonic end effector and control system therefor |
| US11424027B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Method for operating surgical instrument systems |
| US11410259B2 (en) | 2017-12-28 | 2022-08-09 | Cilag Gmbh International | Adaptive control program updates for surgical devices |
| US11896443B2 (en) | 2017-12-28 | 2024-02-13 | Cilag Gmbh International | Control of a surgical system through a surgical barrier |
| US11132462B2 (en) | 2017-12-28 | 2021-09-28 | Cilag Gmbh International | Data stripping method to interrogate patient records and create anonymized record |
| US11056244B2 (en) | 2017-12-28 | 2021-07-06 | Cilag Gmbh International | Automated data scaling, alignment, and organizing based on predefined parameters within surgical networks |
| US11540855B2 (en) | 2017-12-28 | 2023-01-03 | Cilag Gmbh International | Controlling activation of an ultrasonic surgical instrument according to the presence of tissue |
| US11464559B2 (en) | 2017-12-28 | 2022-10-11 | Cilag Gmbh International | Estimating state of ultrasonic end effector and control system therefor |
| US11864728B2 (en) | 2017-12-28 | 2024-01-09 | Cilag Gmbh International | Characterization of tissue irregularities through the use of mono-chromatic light refractivity |
| US10932872B2 (en) | 2017-12-28 | 2021-03-02 | Ethicon Llc | Cloud-based medical analytics for linking of local usage trends with the resource acquisition behaviors of larger data set |
| US11612444B2 (en) | 2017-12-28 | 2023-03-28 | Cilag Gmbh International | Adjustment of a surgical device function based on situational awareness |
| US11051876B2 (en) | 2017-12-28 | 2021-07-06 | Cilag Gmbh International | Surgical evacuation flow paths |
| US11832840B2 (en) | 2017-12-28 | 2023-12-05 | Cilag Gmbh International | Surgical instrument having a flexible circuit |
| US11096693B2 (en) | 2017-12-28 | 2021-08-24 | Cilag Gmbh International | Adjustment of staple height of at least one row of staples based on the sensed tissue thickness or force in closing |
| US20190201112A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Computer implemented interactive surgical systems |
| US11576677B2 (en) | 2017-12-28 | 2023-02-14 | Cilag Gmbh International | Method of hub communication, processing, display, and cloud analytics |
| US11678881B2 (en) | 2017-12-28 | 2023-06-20 | Cilag Gmbh International | Spatial awareness of surgical hubs in operating rooms |
| US11432885B2 (en) | 2017-12-28 | 2022-09-06 | Cilag Gmbh International | Sensing arrangements for robot-assisted surgical platforms |
| US11969216B2 (en) | 2017-12-28 | 2024-04-30 | Cilag Gmbh International | Surgical network recommendations from real time analysis of procedure variables against a baseline highlighting differences from the optimal solution |
| US11602393B2 (en) | 2017-12-28 | 2023-03-14 | Cilag Gmbh International | Surgical evacuation sensing and generator control |
| US10944728B2 (en) | 2017-12-28 | 2021-03-09 | Ethicon Llc | Interactive surgical systems with encrypted communication capabilities |
| US11419667B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Ultrasonic energy device which varies pressure applied by clamp arm to provide threshold control pressure at a cut progression location |
| US11179175B2 (en) | 2017-12-28 | 2021-11-23 | Cilag Gmbh International | Controlling an ultrasonic surgical instrument according to tissue location |
| US11832899B2 (en) | 2017-12-28 | 2023-12-05 | Cilag Gmbh International | Surgical systems with autonomously adjustable control programs |
| US11529187B2 (en) | 2017-12-28 | 2022-12-20 | Cilag Gmbh International | Surgical evacuation sensor arrangements |
| US11324557B2 (en) | 2017-12-28 | 2022-05-10 | Cilag Gmbh International | Surgical instrument with a sensing array |
| US12376855B2 (en) | 2017-12-28 | 2025-08-05 | Cilag Gmbh International | Safety systems for smart powered surgical stapling |
| US11559308B2 (en) | 2017-12-28 | 2023-01-24 | Cilag Gmbh International | Method for smart energy device infrastructure |
| US11109866B2 (en) | 2017-12-28 | 2021-09-07 | Cilag Gmbh International | Method for circular stapler control algorithm adjustment based on situational awareness |
| US11744604B2 (en) | 2017-12-28 | 2023-09-05 | Cilag Gmbh International | Surgical instrument with a hardware-only control circuit |
| US11818052B2 (en) | 2017-12-28 | 2023-11-14 | Cilag Gmbh International | Surgical network determination of prioritization of communication, interaction, or processing based on system or device needs |
| US11857152B2 (en) | 2017-12-28 | 2024-01-02 | Cilag Gmbh International | Surgical hub spatial awareness to determine devices in operating theater |
| US20190201087A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Smoke evacuation system including a segmented control circuit for interactive surgical platform |
| US11589888B2 (en) | 2017-12-28 | 2023-02-28 | Cilag Gmbh International | Method for controlling smart energy devices |
| US12096916B2 (en) | 2017-12-28 | 2024-09-24 | Cilag Gmbh International | Method of sensing particulate from smoke evacuated from a patient, adjusting the pump speed based on the sensed information, and communicating the functional parameters of the system to the hub |
| US10595887B2 (en) | 2017-12-28 | 2020-03-24 | Ethicon Llc | Systems for adjusting end effector parameters based on perioperative information |
| US11284936B2 (en) | 2017-12-28 | 2022-03-29 | Cilag Gmbh International | Surgical instrument having a flexible electrode |
| US11308075B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Surgical network, instrument, and cloud responses based on validation of received dataset and authentication of its source and integrity |
| US11633237B2 (en) | 2017-12-28 | 2023-04-25 | Cilag Gmbh International | Usage and technique analysis of surgeon / staff performance against a baseline to optimize device utilization and performance for both current and future procedures |
| US11311306B2 (en) | 2017-12-28 | 2022-04-26 | Cilag Gmbh International | Surgical systems for detecting end effector tissue distribution irregularities |
| US11213359B2 (en) | 2017-12-28 | 2022-01-04 | Cilag Gmbh International | Controllers for robot-assisted surgical platforms |
| WO2019133144A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Detection and escalation of security responses of surgical instruments to increasing severity threats |
| US11069012B2 (en) | 2017-12-28 | 2021-07-20 | Cilag Gmbh International | Interactive surgical systems with condition handling of devices and data capabilities |
| US11234756B2 (en) | 2017-12-28 | 2022-02-01 | Cilag Gmbh International | Powered surgical tool with predefined adjustable control algorithm for controlling end effector parameter |
| US11257589B2 (en) | 2017-12-28 | 2022-02-22 | Cilag Gmbh International | Real-time analysis of comprehensive cost of all instrumentation used in surgery utilizing data fluidity to track instruments through stocking and in-house processes |
| US11364075B2 (en) | 2017-12-28 | 2022-06-21 | Cilag Gmbh International | Radio frequency energy device for delivering combined electrical signals |
| US11998193B2 (en) | 2017-12-28 | 2024-06-04 | Cilag Gmbh International | Method for usage of the shroud as an aspect of sensing or controlling a powered surgical device, and a control algorithm to adjust its default operation |
| US11786245B2 (en) | 2017-12-28 | 2023-10-17 | Cilag Gmbh International | Surgical systems with prioritized data transmission capabilities |
| US11446052B2 (en) | 2017-12-28 | 2022-09-20 | Cilag Gmbh International | Variation of radio frequency and ultrasonic power level in cooperation with varying clamp arm pressure to achieve predefined heat flux or power applied to tissue |
| US11179208B2 (en) | 2017-12-28 | 2021-11-23 | Cilag Gmbh International | Cloud-based medical analytics for security and authentication trends and reactive measures |
| US11786251B2 (en) | 2017-12-28 | 2023-10-17 | Cilag Gmbh International | Method for adaptive control schemes for surgical network control and interaction |
| US11464535B2 (en) | 2017-12-28 | 2022-10-11 | Cilag Gmbh International | Detection of end effector emersion in liquid |
| US11423007B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Adjustment of device control programs based on stratified contextual data in addition to the data |
| US11389164B2 (en) | 2017-12-28 | 2022-07-19 | Cilag Gmbh International | Method of using reinforced flexible circuits with multiple sensors to optimize performance of radio frequency devices |
| JP2021509061A (ja) | 2017-12-28 | 2021-03-18 | エシコン エルエルシーＥｔｈｉｃｏｎ ＬＬＣ | 状況認識に基づく外科用デバイスの機能の調節 |
| US11672605B2 (en) | 2017-12-28 | 2023-06-13 | Cilag Gmbh International | Sterile field interactive control displays |
| US11304745B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Surgical evacuation sensing and display |
| US11076921B2 (en) | 2017-12-28 | 2021-08-03 | Cilag Gmbh International | Adaptive control program updates for surgical hubs |
| US10966791B2 (en) | 2017-12-28 | 2021-04-06 | Ethicon Llc | Cloud-based medical analytics for medical facility segmented individualization of instrument function |
| US11304699B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Method for adaptive control schemes for surgical network control and interaction |
| US10892995B2 (en) | 2017-12-28 | 2021-01-12 | Ethicon Llc | Surgical network determination of prioritization of communication, interaction, or processing based on system or device needs |
| US12127729B2 (en) | 2017-12-28 | 2024-10-29 | Cilag Gmbh International | Method for smoke evacuation for surgical hub |
| US11304763B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Image capturing of the areas outside the abdomen to improve placement and control of a surgical device in use |
| US12396806B2 (en) | 2017-12-28 | 2025-08-26 | Cilag Gmbh International | Adjustment of a surgical device function based on situational awareness |
| US11266468B2 (en) | 2017-12-28 | 2022-03-08 | Cilag Gmbh International | Cooperative utilization of data derived from secondary sources by intelligent surgical hubs |
| US10892899B2 (en) | 2017-12-28 | 2021-01-12 | Ethicon Llc | Self describing data packets generated at an issuing instrument |
| US10918310B2 (en) | 2018-01-03 | 2021-02-16 | Biosense Webster (Israel) Ltd. | Fast anatomical mapping (FAM) using volume filling |
| US20190201113A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Controls for robot-assisted surgical platforms |
| US10943454B2 (en) | 2017-12-28 | 2021-03-09 | Ethicon Llc | Detection and escalation of security responses of surgical instruments to increasing severity threats |
| US11903601B2 (en) | 2017-12-28 | 2024-02-20 | Cilag Gmbh International | Surgical instrument comprising a plurality of drive systems |
| US11666331B2 (en) | 2017-12-28 | 2023-06-06 | Cilag Gmbh International | Systems for detecting proximity of surgical end effector to cancerous tissue |
| US11291495B2 (en) | 2017-12-28 | 2022-04-05 | Cilag Gmbh International | Interruption of energy due to inadvertent capacitive coupling |
| US11659023B2 (en) | 2017-12-28 | 2023-05-23 | Cilag Gmbh International | Method of hub communication |
| US12458351B2 (en) | 2017-12-28 | 2025-11-04 | Cilag Gmbh International | Variable output cartridge sensor assembly |
| US11166772B2 (en) | 2017-12-28 | 2021-11-09 | Cilag Gmbh International | Surgical hub coordination of control and communication of operating room devices |
| US11100631B2 (en) | 2017-12-28 | 2021-08-24 | Cilag Gmbh International | Use of laser light and red-green-blue coloration to determine properties of back scattered light |
| US11376002B2 (en) | 2017-12-28 | 2022-07-05 | Cilag Gmbh International | Surgical instrument cartridge sensor assemblies |
| US11419630B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Surgical system distributed processing |
| US12062442B2 (en) | 2017-12-28 | 2024-08-13 | Cilag Gmbh International | Method for operating surgical instrument systems |
| US10987178B2 (en) | 2017-12-28 | 2021-04-27 | Ethicon Llc | Surgical hub control arrangements |
| US11771487B2 (en) | 2017-12-28 | 2023-10-03 | Cilag Gmbh International | Mechanisms for controlling different electromechanical systems of an electrosurgical instrument |
| US11253315B2 (en) | 2017-12-28 | 2022-02-22 | Cilag Gmbh International | Increasing radio frequency to create pad-less monopolar loop |
| US11273001B2 (en) | 2017-12-28 | 2022-03-15 | Cilag Gmbh International | Surgical hub and modular device response adjustment based on situational awareness |
| US11317937B2 (en) | 2018-03-08 | 2022-05-03 | Cilag Gmbh International | Determining the state of an ultrasonic end effector |
| US10758310B2 (en) | 2017-12-28 | 2020-09-01 | Ethicon Llc | Wireless pairing of a surgical device with another device within a sterile surgical field based on the usage and situational awareness of devices |
| US11278281B2 (en) | 2017-12-28 | 2022-03-22 | Cilag Gmbh International | Interactive surgical system |
| US10695081B2 (en) | 2017-12-28 | 2020-06-30 | Ethicon Llc | Controlling a surgical instrument according to sensed closure parameters |
| US11937769B2 (en) | 2017-12-28 | 2024-03-26 | Cilag Gmbh International | Method of hub communication, processing, storage and display |
| US11160605B2 (en) | 2017-12-28 | 2021-11-02 | Cilag Gmbh International | Surgical evacuation sensing and motor control |
| US10898622B2 (en) | 2017-12-28 | 2021-01-26 | Ethicon Llc | Surgical evacuation system with a communication circuit for communication between a filter and a smoke evacuation device |
| US11559307B2 (en) | 2017-12-28 | 2023-01-24 | Cilag Gmbh International | Method of robotic hub communication, detection, and control |
| US11969142B2 (en) | 2017-12-28 | 2024-04-30 | Cilag Gmbh International | Method of compressing tissue within a stapling device and simultaneously displaying the location of the tissue within the jaws |
| US11202570B2 (en) | 2017-12-28 | 2021-12-21 | Cilag Gmbh International | Communication hub and storage device for storing parameters and status of a surgical device to be shared with cloud based analytics systems |
| US10849697B2 (en) | 2017-12-28 | 2020-12-01 | Ethicon Llc | Cloud interface for coupled surgical devices |
| US20190206569A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Method of cloud based data analytics for use with the hub |
| US11896322B2 (en) | 2017-12-28 | 2024-02-13 | Cilag Gmbh International | Sensing the patient position and contact utilizing the mono-polar return pad electrode to provide situational awareness to the hub |
| US11147607B2 (en) | 2017-12-28 | 2021-10-19 | Cilag Gmbh International | Bipolar combination device that automatically adjusts pressure based on energy modality |
| US12303159B2 (en) | 2018-03-08 | 2025-05-20 | Cilag Gmbh International | Methods for estimating and controlling state of ultrasonic end effector |
| US11399858B2 (en) | 2018-03-08 | 2022-08-02 | Cilag Gmbh International | Application of smart blade technology |
| US11259830B2 (en) | 2018-03-08 | 2022-03-01 | Cilag Gmbh International | Methods for controlling temperature in ultrasonic device |
| US11986233B2 (en) | 2018-03-08 | 2024-05-21 | Cilag Gmbh International | Adjustment of complex impedance to compensate for lost power in an articulating ultrasonic device |
| US11278280B2 (en) | 2018-03-28 | 2022-03-22 | Cilag Gmbh International | Surgical instrument comprising a jaw closure lockout |
| US11219453B2 (en) | 2018-03-28 | 2022-01-11 | Cilag Gmbh International | Surgical stapling devices with cartridge compatible closure and firing lockout arrangements |
| US11471156B2 (en) | 2018-03-28 | 2022-10-18 | Cilag Gmbh International | Surgical stapling devices with improved rotary driven closure systems |
| US11096688B2 (en) | 2018-03-28 | 2021-08-24 | Cilag Gmbh International | Rotary driven firing members with different anvil and channel engagement features |
| US11129611B2 (en) | 2018-03-28 | 2021-09-28 | Cilag Gmbh International | Surgical staplers with arrangements for maintaining a firing member thereof in a locked configuration unless a compatible cartridge has been installed therein |
| US11090047B2 (en) | 2018-03-28 | 2021-08-17 | Cilag Gmbh International | Surgical instrument comprising an adaptive control system |
| US10973520B2 (en) | 2018-03-28 | 2021-04-13 | Ethicon Llc | Surgical staple cartridge with firing member driven camming assembly that has an onboard tissue cutting feature |
| US11259806B2 (en) | 2018-03-28 | 2022-03-01 | Cilag Gmbh International | Surgical stapling devices with features for blocking advancement of a camming assembly of an incompatible cartridge installed therein |
| US11207067B2 (en) | 2018-03-28 | 2021-12-28 | Cilag Gmbh International | Surgical stapling device with separate rotary driven closure and firing systems and firing member that engages both jaws while firing |
| US11357503B2 (en) | 2019-02-19 | 2022-06-14 | Cilag Gmbh International | Staple cartridge retainers with frangible retention features and methods of using same |
| US11317915B2 (en) | 2019-02-19 | 2022-05-03 | Cilag Gmbh International | Universal cartridge based key feature that unlocks multiple lockout arrangements in different surgical staplers |
| US11298130B2 (en) | 2019-02-19 | 2022-04-12 | Cilag Gmbh International | Staple cartridge retainer with frangible authentication key |
| US11464511B2 (en) | 2019-02-19 | 2022-10-11 | Cilag Gmbh International | Surgical staple cartridges with movable authentication key arrangements |
| US11369377B2 (en) | 2019-02-19 | 2022-06-28 | Cilag Gmbh International | Surgical stapling assembly with cartridge based retainer configured to unlock a firing lockout |
| USD964564S1 (en) | 2019-06-25 | 2022-09-20 | Cilag Gmbh International | Surgical staple cartridge retainer with a closure system authentication key |
| USD950728S1 (en) | 2019-06-25 | 2022-05-03 | Cilag Gmbh International | Surgical staple cartridge |
| USD952144S1 (en) | 2019-06-25 | 2022-05-17 | Cilag Gmbh International | Surgical staple cartridge retainer with firing system authentication key |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721219A (en) * | 1993-02-10 | 1998-02-24 | Astra Pharmaceuticals Ltd. | N-alkyl-2-substituted ATP analogues and administration to inhibit platelet aggregation |
| US20060121086A1 (en) * | 2003-10-21 | 2006-06-08 | Boyer Jose L | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| WO2007024472A2 (en) * | 2005-08-19 | 2007-03-01 | Eli Lilly And Company | USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES |
| US20070082840A1 (en) * | 2004-03-05 | 2007-04-12 | Porter R S | Combination therapy for inhibition of platelet aggregation |
| US20070254324A1 (en) * | 2006-04-28 | 2007-11-01 | Dade Behring Marburg Gmbh | Method for determination of platelet function under flow conditions |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2530247B1 (fr) * | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| US5256559A (en) | 1988-03-04 | 1993-10-26 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| ID21635A (id) | 1996-12-20 | 1999-07-08 | Astra Pharma Prod | Komposisi farmasi untuk pengeringan beku |
| SE9702680D0 (sv) | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
| SE9904377D0 (sv) | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| ATE398624T1 (de) * | 2000-07-06 | 2008-07-15 | Daiichi Sankyo Co Ltd | Säure-additionssalze von hydropyridinderivaten |
| US7132408B2 (en) * | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| ATE536889T1 (de) | 2003-07-08 | 2011-12-15 | Accumetrics Inc | Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten |
| US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| CA2623449C (en) | 2008-03-27 | 2010-11-02 | Lance Baldo | A novel use of bivalirudin in the treatment of acute coronary syndrome |
| US20130303477A1 (en) | 2008-05-13 | 2013-11-14 | The Medicines Company | Maintenance of Platelet Inhibition During Antiplatelet Therapy |
| US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US8759316B2 (en) | 2008-05-13 | 2014-06-24 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US20120141468A1 (en) | 2008-05-13 | 2012-06-07 | Lisa Ruderman Chen | Maintenance of platelet inhibition during antiplatelet therapy |
| US8680052B1 (en) * | 2013-03-09 | 2014-03-25 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| WO2009140092A1 (en) | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| PT2498731T (pt) | 2009-11-11 | 2020-02-21 | Chiesi Farm Spa | Métodos de tratamento ou prevenção de uma trombose de endoprótese |
| US20130040898A1 (en) | 2010-04-29 | 2013-02-14 | Pär Johansson | Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof |
-
2009
- 2009-05-04 WO PCT/US2009/042681 patent/WO2009140092A1/en not_active Ceased
- 2009-05-13 EP EP09747490.2A patent/EP2276541B1/en active Active
- 2009-05-13 CN CN2009801266781A patent/CN102089035A/zh active Pending
- 2009-05-13 CA CA2724470A patent/CA2724470C/en active Active
- 2009-05-13 US US12/990,332 patent/US8871736B2/en active Active
- 2009-05-13 AU AU2009246396A patent/AU2009246396B2/en active Active
- 2009-05-13 PT PT97474902T patent/PT2276541T/pt unknown
- 2009-05-13 LT LTEP09747490.2T patent/LT2276541T/lt unknown
- 2009-05-13 SI SI200931550A patent/SI2276541T1/sl unknown
- 2009-05-13 JP JP2011509659A patent/JP5792059B2/ja active Active
- 2009-05-13 BR BRPI0912693A patent/BRPI0912693B8/pt active IP Right Grant
- 2009-05-13 HR HRP20161443TT patent/HRP20161443T1/hr unknown
- 2009-05-13 DK DK09747490.2T patent/DK2276541T3/en active
- 2009-05-13 WO PCT/US2009/043820 patent/WO2009140407A1/en not_active Ceased
- 2009-05-13 HU HUE09747490A patent/HUE031704T2/hu unknown
- 2009-05-13 ES ES09747490.2T patent/ES2601524T3/es active Active
- 2009-05-13 PL PL09747490T patent/PL2276541T3/pl unknown
-
2013
- 2013-12-18 JP JP2013260851A patent/JP2014077005A/ja active Pending
-
2016
- 2016-04-24 US US15/136,979 patent/US10022391B2/en active Active
- 2016-11-03 CY CY20161101124T patent/CY1118653T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721219A (en) * | 1993-02-10 | 1998-02-24 | Astra Pharmaceuticals Ltd. | N-alkyl-2-substituted ATP analogues and administration to inhibit platelet aggregation |
| US20060121086A1 (en) * | 2003-10-21 | 2006-06-08 | Boyer Jose L | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| US20070082840A1 (en) * | 2004-03-05 | 2007-04-12 | Porter R S | Combination therapy for inhibition of platelet aggregation |
| WO2007024472A2 (en) * | 2005-08-19 | 2007-03-01 | Eli Lilly And Company | USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES |
| US20070254324A1 (en) * | 2006-04-28 | 2007-11-01 | Dade Behring Marburg Gmbh | Method for determination of platelet function under flow conditions |
Non-Patent Citations (2)
| Title |
|---|
| GREENBAUM ET AL.,: "initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: result from a 2-part, phase ii, multicenter, randomized, placebo- and active-controlled trial", 《AMERICAN HEART JOURNAL》 * |
| STEVEN R. STEINHUBL, ET AL.,: "Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect", 《THROMBOSIS RESEARCH》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115120606A (zh) * | 2013-03-09 | 2022-09-30 | 奇斯药制品公司 | 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 |
| CN110740736A (zh) * | 2017-06-23 | 2020-01-31 | 奇斯药制品公司 | 预防体-肺动脉分流术血栓形成的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK2276541T3 (en) | 2016-11-28 |
| LT2276541T (lt) | 2016-12-12 |
| US20170049798A1 (en) | 2017-02-23 |
| US8871736B2 (en) | 2014-10-28 |
| EP2276541A4 (en) | 2012-05-09 |
| HUE031704T2 (hu) | 2017-07-28 |
| EP2276541B1 (en) | 2016-08-03 |
| US20110288043A1 (en) | 2011-11-24 |
| ES2601524T3 (es) | 2017-02-15 |
| PT2276541T (pt) | 2016-11-10 |
| SI2276541T1 (sl) | 2017-02-28 |
| CA2724470A1 (en) | 2009-11-19 |
| JP2011520899A (ja) | 2011-07-21 |
| JP2014077005A (ja) | 2014-05-01 |
| BRPI0912693A2 (pt) | 2019-01-15 |
| AU2009246396B2 (en) | 2015-07-09 |
| BRPI0912693B8 (pt) | 2021-05-25 |
| US10022391B2 (en) | 2018-07-17 |
| HRP20161443T1 (hr) | 2016-12-30 |
| JP5792059B2 (ja) | 2015-10-07 |
| CA2724470C (en) | 2018-01-02 |
| EP2276541A1 (en) | 2011-01-26 |
| CY1118653T1 (el) | 2017-07-12 |
| AU2009246396A1 (en) | 2009-11-19 |
| PL2276541T3 (pl) | 2017-08-31 |
| BRPI0912693B1 (pt) | 2021-05-11 |
| WO2009140092A1 (en) | 2009-11-19 |
| WO2009140407A1 (en) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102089035A (zh) | 抗血小板治疗中血小板抑制的维持 | |
| Salzwedel et al. | Perioperative goal-directed hemodynamic therapy based on radial arterial pulse pressure variation and continuous cardiac index trending reduces postoperative complications after major abdominal surgery: a multi-center, prospective, randomized study | |
| CA2829947C (en) | Dosing regimens for the treatment of fabry disease | |
| CA2844931C (en) | Maintenance of platelet inhibition during antiplatelet therapy | |
| US20230210880A1 (en) | Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events | |
| BR112012011298B1 (pt) | Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos | |
| US9320754B2 (en) | Maintenance of platelet inhibition during antiplatelet therapy | |
| US20130324492A1 (en) | Maintenance of Platelet Inhibition During Antiplatelet Therapy | |
| Park et al. | Noninvasive hemoglobin monitoring for maintaining hemoglobin concentration within the target range during major noncardiac surgery: A randomized controlled trial | |
| Hajizadeh et al. | In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris | |
| CN102600146B (zh) | 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法 | |
| Singh et al. | Associations of iron sucrose and intradialytic blood pressure | |
| WO2014209389A1 (en) | Maintenance of platelet inhibition during antiplatelet therapy | |
| Koomanachai et al. | Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy | |
| Messina et al. | Effects of intravenous paracetamol on mean arterial pressure in critically ill patients: A systematic review and meta-analysis with trial sequential analysis | |
| Han et al. | Is Dosage Adjustment Based on Age Necessary for Intravenous Lidocaine in Patients Undergoing General Anesthesia: A Prospective Multi-Arm Comparative Study | |
| Carvalho et al. | Plasmatic vasopressin in patients undergoing conventional infra-renal abdominal aorta aneurysm repair | |
| Kollars et al. | Tolerance to miotic effects of opioids | |
| Kikuchi et al. | A Case of Takotsubo Cardiomyopathy Diagnosed After Postponement of Surgery Due to Hypotension and Electrocardiogram Abnormality Upon Entering the Operating Room | |
| Lal et al. | AN EFFECTIVENESS, SAFETY AND TOLERABILITY STUDY OF AZILSARTAN AND TELMISARTAN IN PATIENTS OF ESSENTIAL HYPERTENSION: A RANDOMIZED AND OPEN-LABEL STUDY | |
| Charter et al. | Shaheed Syed Nazrul Islam Medical College, Kishoreganj, Bangladesh | |
| Barsh et al. | A Case Report of Anaphylactic Shock to Tirzepatide | |
| Belda et al. | Cornelie Salzwedel1, Jaume Puig2, Arne Carstens3, Berthold Bein3, Zsolt Molnar4, Krisztian Kiss4, Ayyaz Hussain5 | |
| Kohli et al. | Potentially dangerous fracture of the needleless interlink vial access cannula | |
| WO2015054542A1 (en) | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110608 |